Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MP Materials (MP) vs Novavax Inc (NVAX) Price & Performance

MP MaterialsTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

MP Materials vs Novavax Inc — how do they compare? MP Materials trades at $54.53 (market cap $9.86B), while Novavax Inc trades at $9.88 (market cap $1.68B). The key difference: MP Materials is far larger — about 5.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, MP Materials nearer its low. Which is the better fit depends on your goals.

MPNVAX
Market Cap
$9.86B$1.68B
Sector
IndustrialsHealth
52-Week High
$98.65$11.19
52-Week Low
$38.10$6.22
Enterprise Value
$9.34B$1.26B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MP Materials

No Aura AI signal available yet.

Novavax Inc

Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.

The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MP Materials

MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.

Read more on MP

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX